Antithrombin Supplementation during Extracorporeal Membrane Oxygenation: Study Protocol for a Pilot Randomized Clinical Trial

doi:10.21203/rs.2.62/v2

Download PDF

Study protocol

Antithrombin Supplementation during Extracorporeal Membrane Oxygenation: Study Protocol for a Pilot Randomized Clinical Trial

https://doi.org/10.21203/rs.2.62/v2

This work is licensed under a CC BY 4.0 License

Journal Publication

published 11 Jun, 2019

Read the published version in Trials →

You are reading this latest preprint version

Background: Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO). Acquired AT deficiency during ECMO is common, but formal recommendation on target, timing, and rate of AT supplementation is lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT supplementation in patients requiring veno-venous ECMO for respiratory failure. Methods: GATRA is a phase 3, prospective, randomized, single blinded multicenter controlled two-arm trial. Patients undergoing veno-venous ECMO will be randomized to either receive AT supplementation to maintain a functional AT level between 80%-120% (AT supplementation group) or not (control group) for the entire ECMO course. In both study groups anticoagulation will be provided with unfractionated heparin following a standardized protocol. The primary endpoint will be the dose of heparin required to maintain ratio of activated partial thromboplastin time between 1.5-2. Secondary endpoints will be the adequacy of anticoagulation and the incidence of hemorrhagic and thrombotic complications. Discussion: GATRA is a pilot trial that will test the efficacy of a protocol of AT supplementation in decreasing the heparin dose and improving anticoagulation adequacy during ECMO. If positive, it might provide the basis for a future larger trial aimed at verifying the impact of AT supplementation on a composite outcome endpoint including hemorrhagic events, transfusion requirements and mortality.

Trial registration

ClinicalTrials.gov, NCT03208270. Registered on 5 July 2017.

General Medicine

Extracorporeal membrane oxygenation (ECMO) is a temporary life support for patients with severe acute respiratory failure refractory to conventional treatment and its use is continuously increasing worldwide(1). Since exposure of blood to non-biologic surface of the extracorporeal circuit induces a pro-thrombotic state and an inflammatory response, the use of ECMO necessitates the maintenance of hemostatic balance to minimize the risk of both hemorrhagic and thrombotic complications(2). Consequently, to avoid clotting in the extracorporeal circuit and in the patient, anticoagulation is necessary, but it increases risk of bleeding(3). A recent retrospective analysis on more than 2000 patients reported bleeding and thrombotic complications with a frequency up to 45% and 60% respectively, with major impact on outcome(4).

Anticoagulation management during ECMO is usually based on continuous infusion of unfractionated heparin(5,6). Heparin effect is strictly dependent on antithrombin (AT) activity in plasma(7,8). Acquired AT deficiency during ECMO is common and multifactorial(9): possible mechanisms include consumption due to activated coagulation and long-term anticoagulation, but also impaired synthesis, degradation by elastase from activated neutrophils and disseminated intravascular coagulation. Antithrombin deficiency contributes to heparin resistance, with difficulty in achieving therapeutic anticoagulation and increased heparin dose(7). Theoretically, normalization of AT levels should decrease heparin requirements to achieve a proper anticoagulation target(9). This may have a relevant clinical impact because risk of bleeding during ECMO is reasonably associated with higher heparin dosage and a better control of anticoagulation may improve patients’ outcome(10). However, formal recommendation on target, timing, and rate of AT supplementation during ECMO is lacking.

Given this lack of current knowledge, we designed a prospective randomized controlled clinical trial to evaluate the effects of a protocol of AT supplementation to achieve and maintain a normal AT activity on heparin dose, level of anticoagulation, bleeding and thrombotic complications in adult patients undergoing ECMO for respiratory failure.

The results of this study will clarify some of the unanswered issues on AT supplementation during ECMO and will eventually provide the basis for a subsequent larger study on outcome.

Study design:

The GATRA Study is a pilot, prospective, randomized, single blinded multicenter controlled two-arm trial that will be performed on adult patients undergoing veno-venous ECMO for severe respiratory failure. The study will be conducted in adherence to the principles of the World Medical Association’s Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act (WMO). The Ethics Committee of the coordinating center (Comitato Etico Milano Area B) approved the protocol on April 18th, 2017 (Version 1.6.7 - April 4, 2017), approval of local Ethics Committee will be required before starting the trial in the participating centers. The study was authorized by AIFA (Agenzia Italiana del Farmaco) on April 11th 2017 (EudraCT number: 2016-004534-23) and registered at www.clinicaltrials.gov with code NCT03208270. Informed consent to participate in the clinical trial will be obtained, and information on the clinical trial will be given to each patient. In case the patient is not capable of giving informed consent at the time of enrollment, a deferred consent will be given. The informed consent will be sought by the investigator from the patient, and the information about the study will be given to the patient or his/her legally designated representative, as soon as possible. In case the patient does not consent to the study, he/she will be informed of the right to object to the use of data obtained from the clinical trial. The Standard protocol items: recommendation for interventional trials (SPIRIT) checklist can be found in Additional file 1 and the SPIRIT figure is included in the main body of the manuscript (Fig. 1).

Setting:

The GATRA trial will be performed in the Intensive Care Units of Italian ECMO referral centers. The coordinating center will be Fondazione IRCCS Ca’ Granda – Policlinico Maggiore Hospital in Milan, Italy.

Study population:

Consecutive adult patients admitted to the participating Centers requiring veno-venous ECMO as a support for respiratory failure will be enrolled in the study. Exclusion criteria will be: pre-existent heparin-induced thrombocytopenia; other contraindications to heparin use (namely high risk of bleeding after major surgery prompting the decision to start ECMO without systemic anticoagulation). The Consolidated Standards of Reporting Trials (CONSORT) diagram of GATRA trial is presented in Figure 2.

Randomization:

As soon as the clinical decision to initiate ECMO is made, the patient will be enrolled in the study. Patients will be block randomized per center through an online automatic centralized and computerized system to one of the two groups (1:1 ratio): AT supplementation group and control group.

Interventions:

Antithrombin supplementation group:

Patients randomized to the AT supplementation group will receive supplementation of AT concentrate to maintain a functional AT level between 80%-120%. AT level will be measured prior to ECMO start and then once daily and supplementation adjusted accordingly. In the study group AT concentrate supplementation will be interrupted when AT levels exceeds 120% and resumed as soon as levels drops below 80%. The protocol for AT supplementation is illustrated in Figure 3.

Control group:

Patients randomized to the control group will not receive supplementation of AT unless heparin resistance occurs. The following safety criteria will be applied to define “heparin resistance”: when a patient in the control group requires more than 35 IU/Kg/h of heparin and his/her AT plasma level is equal or lower than 50%. Dosage regimen for AT supplementation in the control group will follow the same supplementation algorithm as in the treatment group. AT will be supplemented to achieve an AT plasma level higher than 50%. Antithrombin level will be measured prior to ECMO start and then once daily.

Anticoagulation protocol for both groups:

In both study groups anticoagulation during ECMO will be provided with unfractionated heparin following the institutional protocol of the coordinating center as previously published(10) (Figure 4). Briefly, a heparin bolus of 50 to 70 UI/kg (depending on baseline activated partial thromboplastin time - aPTT - value) will be administered at ECMO start, followed by 18 UI/kg/h continuous infusion. For the first 12 hours after ECMO start, anticoagulation will be monitored with Activated Clotting Time (ACT) (therapeutic range 180-210 seconds, performed every 1 or 2 hours according to the standardized protocol). From the 13th hour on, anticoagulation will be guided by aPTT, with a target range of aPTT patient to normal ratio of 1.5 - 2.0. Frequency of aPTT measurements may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When aPTT value falls well below the desired range a bolus of heparin will be administered. When too high, infusion will be stopped for either 30 or 60 minutes. In both groups the following safety criteria will be used: in case of major surgery, during the first 24 hours after operation, minimal levels of anticoagulation will be allowed to minimize the risk of bleeding. In case of minor bleeding (i.e. dripping from site of vascular catheters cannulation) physicians shall maintain anticoagulation target to the lower level (i.e. aPTT ratio 1.5). In case of clinically significant bleeding heparin infusion may be interrupted until bleeding ceases; infusion will be restored starting at 50-70% of the pre-existing dose. No changes will be done in AT dosage regimen.

Criteria for transfusions of blood products and replacement of the ECMO circuit:

For the entire duration of the study hemoglobin will be maintained > 10 g/dL, platelet count > 50000/mm3 and fibrinogen > 150 mg/dL, through packed red blood cells, platelets and fresh frozen plasma and/or fibrinogen concentrate transfusions, respectively.

To standardize the clinical decision to replace the ECMO circuit with a new one, an ad hoc “circuit change-out score” was developed that considers the performance of the oxygenator, signs of coagulation activation by the extracorporeal circuit (e.g., drop in platelets count, increase in D-dimer and decrease in fibrinogen levels) and the presence of hemolysis. The “circuit change-out score” includes two different conditions (A and B), defined by different sets of criteria. Condition A requires all the following three criteria to be satisfied: decrease in platelet count greater than 50% in 48 hours; decrease in fibrinogen level greater than 33% in 48 hours; increase in D-dimer level greater than 100% with D-dimer level higher than 30000 ng/ml. Condition B requires two out of the following three criteria to be satisfied: platelet count lower than 50000/ml; fibrinogen lower than 150 mg/dl; D-dimer higher than 50000 ng/ml, provided that D-dimer elevation is one of the two “B” conditions.

Stopping rules:

Patients will be supplemented with AT during ECMO according to the assigned group and followed-up for the entire duration of ECMO. Antithrombin supplementation will be stopped at ECMO discontinuation.

Premature discontinuation of the study will be allowed when one of the following conditions occurs: 1) death; 2) onset of heparin induced thrombocytopenia requiring shift to an alternative anticoagulant drug to heparin; 3) unexpected circumstances that prevent proper heparin or AT supplementation.

End of follow-up

Enrolled patients will be observed until ICU discharge or death, whichever comes first.

Study endpoints

Primary endpoint

~~The primary endpoint will be the dose of unfractioned heparin required to maintain aPTT ratio between 1.5-2.~~ The primary endpoint will be the amount of heparin infused to each patient, calculated as the total administered heparin per kg of body weight (including boluses), divided by the total duration of heparin infusion in hours (IU/Kg/h).

Secondary endpoints

Adequacy of anticoagulation will be assessed through anti-Xa levels.

The study will also provide a preliminary evaluation of the safety of AT supplementation by comparing the incidence of the following adverse events in the two study groups: bleeding complications, classified according to a modified version of the Bleeding Academic Research Consortium score to our clinical settings(11,12); blood products transfusion requirements; patient’s or circuit thrombosis.

Data collection

At enrollment, we will anonymously collect patients’ demographic information (e.g., age, sex, height, weight), past (e.g., chronic medications including anticoagulant and antiplatelet drugs) and recent (e.g., etiology of the acute respiratory failure) medical history, ECMO configuration with cannulation sites. A blood sample will be drawn from patients to test inherited or acquired thrombophilia (proteins C and S, Factor (F) V G1691A and FII G20210A, lupus anticoagulant, anti-cardiolipin and anti-β2-glycoprotein 1 antibodies).

The following data will be recorded every day for the whole study duration: daily heparin dosage; coagulation parameters (including ddimer, fibrinogen, aPTT ratio, PT ratio, anti-factor Xa, antithrombin activity, ACT); complete blood count; indexes of hemolysis (hemoglobin, free hemoglobin and aptoglobin levels); transfusion of blood products.

Bleeding and thrombotic events will also be recorded. Within 24 hours after ECMO removal, a doppler ultrasonography of the cannulated vessels and of the vena cava will be performed to exclude thrombosis due to vascular cannulation. Functional ECMO parameters will be evaluated once per day (membrane oxygenator shunt, blood flow resistance, oxygenation performance) and recorded.

Evaluation of clinical outcome will include duration of ECMO, ICU length of stay and survival at 28 days.

Collected data will be entered in an electronic case report form (eCRF) available online at a dedicated website (https://ecmostudy.fbk.eu), with protected individual access for each participating center. Patient data will be anonymous and coded according to a number. The eCRF includes tools to promote data quality, such as range checks for data values. Data monitoring will be performed by means of queries on the database done by statisticians and analyzed to identify abnormalities and inconsistencies.

Statistical Considerations

All statistical analyses will be done with Stata version 14.1 (StataCorp, College Station, TX) in the coordinating centers at the Epidemiology Unit of Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico di Milano, Milan, Italy.

Sample size

Sample size is calculated using the confidence interval approach upon the primary outcome measure of reduction of heparin dose in the study group treated with AT to maintain a normal AT plasma level (considered to be normal a level higher than 80%) compared to the control group. Preliminary data from patients in ECMO, cared for with the same heparin titration protocol of this study, showed that mean heparin dosage was 18 IU/kg/h and 13 IU/kg/h in patients with AT activity lower and higher than the median (73.5%), respectively. Assuming an estimated difference of 5 IU/Kg/h of heparin between the two groups, a sample size of 40 patients (20 in each treatment group) would yield a 95% confidence intervals of average heparin reduction from 1 to 9 IU/Kg/h).

Proposal for analysis

Baseline variables will be compared between each randomized arm to assess the randomization performance and baseline balance between arms. We will not perform statistical testing for baseline comparison between arms, because any differences in baseline characteristics are consequences of chance due to randomization. All analyses will be conducted in accordance with the intention-to-treat principle and in accordance to the CONSORT statement.

For the primary and secondary outcomes, continuous variables will be reported as means ± standard deviations or medians and 25-75% interquartile ranges. Categorical variables will be reported as absolute and relative frequencies. Differences between groups will be tested using Mann-Whitney and chi-square or Fisher’s exact tests, as appropriate. Estimates of the effects and their confidence intervals will be also reported. In case of evident imbalances for key baseline variables between treated and controls, we will perform statistical adjustment using regression models.

For repeated outcomes within subject the association between AT dosage, heparin dosage, bleeding and monitoring methods will be evaluated using random-effect models.

Study organization

This is an investigator initiated trial. Two principal investigators (MP and GG) designed the study protocol. Each participating center will indicate a local investigator in charge of the study. The principal investigators are responsible for administrative management and communication with the local investigators and for helping the participating clinical sites in trial management, record keeping and data management. The study will be conducted with the financial support of Grifols (GATRA – Antithrombin Research Awards 2016). Funders will not have any role in the analysis and interpretation of the study results and in the decision to submit the report for publication. The local investigators guarantee the integrity of data collection. All adverse events will be monitored by the coordinating center and reported to AIFA according to the national legislation. Specific patient insurance will be granted to cover all unexpected adverse events caused by the study interventions.

Ancillary study:

The rationale for antithrombin supplementation during ECMO is also based on its coagulation-independent anti-inflammatory effects. Some of these mechanisms include endothelial release of prostacyclin that inhibits aggregation and activation of platelets(13,14) and the reduction of various cytokines and chemokines from the endothelial cells(15,16).

To evaluate markers of inflammation, epithelial and endothelial damage, 4 aliquots of plasma, 0.5 ml each, will be obtained from each patient in the GATRA study, by centrifugation of EDTA blood at 3000 RPM for 15 min at 4 °C, prior to ECMO start, 24 hours after ECMO start, 72 hours after ECMO start, before ECMO removal and seven days after ECMO removal (or before discharge from the ICU if this happens before). Then aliquots will be stored, shortly after collection, at -80°C until levels TNF-alpha, IL-1beta, IL-6, IL-8, IL-10, Endocan and Syndecan will be measured. At the same time points we will also collect blood to evaluate the transcriptional profile of circulating cells in whole blood. To identify changes in the transcriptional activation of genes involved in inflammation, epithelial, and endothelial damage, 2.5 ml of whole blood will be collected in RNA paxGene tubes prior to ECMO start, 24 and 72 hours after ECMO start. Specimen will be stored at -20°C until transcriptome profiling will be performed(17).

GATRA is a pilot randomized controlled trial aimed at testing a protocol of AT supplementation in patients on ECMO for severe respiratory failure. It will assess the feasibility and the safety of prolonged AT supplementation to target normal AT levels and its efficacy in decreasing the heparin dose and improving anticoagulation adequacy. If positive, it might provide the basis for a future larger trial aimed at verifying the impact of AT supplementation on a composite outcome endpoint including hemorrhagic events, transfusion requirements and mortality.

Antithrombin supplementation during ECMO

Heparin mainly exerts its anticoagulant effect by binding AT and facilitating the inhibition of thrombin by AT. When heparin binds to AT, converts AT from a slow to a rapid thrombin inhibitor. Therefore, the therapeutic activity of heparin depends on the availability of circulating AT.. The heparin/AT also inhibits factor-Xa and to a less extent other activated coagulation factors (Xa, IXa, XIa, and XIIa)(18). Another possible anticoagulant mechanism of heparin includes the release of tissue factor pathway inhibitor from endothelial cells(19). Although AT is needed by heparin to properly exploit its anticoagulant activity, there is no consensus on AT supplementation during ECMO. Guidelines suggest to supplement AT in ECMO only when its deficiency coexists with heparin resistance(6). Few studies evaluated the effect of AT supplementation during ECMO without a consensus on the target level to be maintained. Small and retrospective studies in the pediatric population examined the administration of AT during ECMO but yielded inconclusive results, with some reporting no effects on heparin dose and bleeding(20–22) and other observing decreased heparin requirements(23–25) and less transfusions(25). These contrasting results might be explained by the high variability in dosing schemes, target levels, timing and duration of AT supplementation.

Development of the protocol for AT supplementation: practical and operational issues

Since dosing recommendations are not provided for acquired AT deficiency, the protocol for AT supplementation was developed following manufacturer recommendations for hereditary deficiency. Supplementation dosing is based on patient body weight and the difference between the actual and the desired AT activity. A level of AT activity corresponding to the normal range (80-120%) was chosen as the target for supplementation. The calculated dose was rounded up to the nearest vial size and dose tiers were created using ranges of AT activity to minimize bedside calculations. The protocol ~~provides~~ mandates, for patients in the AT supplementation group, the administration of a loading dose of AT upon ECMO cannulation. As the level of AT activity before ECMO start was expected not to be available for most patients, the loading dose is based solely on the patient body weight. Subsequent dose adjustments are based on the patient body weight and the plasma AT activity, which must be measured daily. Patients with a plasma AT activity between 80-120% will receive a maintenance dose, which will be increased by 1000 UI if the plasma AT activity is lower than 80%. Observational studies suggest that intermittent administration of AT is less effective than continuous infusion in correcting AT deficiency; moreover, rapid AT binding to heparin complexes after bolus administration could theoretically increase the risk for bleeding. Based on our and other ECMO centers(26,27) clinical experience, administration of AT via an extended infusion decreases heparin rate modifications and avoids AT levels fluctuations, without increasing the risk of major bleeding. Therefore, the protocol prescribes AT administration by extended infusion both for loading and maintenance doses.

Study endpoints

Hemorrhagic complications remain a major cause of morbidity and mortality in ECMO patients(4). Hence, protocols to guide anticoagulation management are key in the management of these patients. Physiological considerations suggest that normalization of AT levels might improve adequacy of heparin anticoagulation and possibly decrease the risk of bleeding. Indeed, in adult patients undergoing ECMO for respiratory failure, lower AT levels were associated with increased need for transfusion(26) and AT supplementation facilitated achievement of target anticoagulation without increasing heparin dosage(27). Higher degree of anticoagulation(28) is associated with hemorrhagic events during ECMO, but risk of bleeding is multifactorial and does not depend solely on anticoagulation. We chose the reduction of heparin dose as the primary endpoint for this pilot trial, however it is conceivable that larger studies will be needed to detect the hypothesized effect on clinical outcome.

Study strengths and limitations

One of the strengths of the study is that the protocol contains a well-defined heparin anticoagulation protocol, which has already been adopted in a previous multicenter trial(29). This should facilitate its application and minimize deviations in anticoagulation management which could jeopardize the effect of AT supplementation on study endpoints. Although the decision to transfuse blood products is clinical, the protocol recommends well-defined targets for hemoglobin, platelet count and fibrinogen. Similarly, criteria for considering replacement of the ECMO circuit are provided.

One limitation of the GATRA trial is that blinding is not possible due to the nature of the intervention. However, the factors that can potentially affect the primary outcome (in particular heparin dose adjustments and transfusion of blood products) are regulated by the protocol.

The GATRA trial is currently recruiting patients. The protocol was approved by the Ethical Committee of coordinating center on April 18th, 2017. The first patient was enrolled on 8 August 2017, until September 9th 2018, 36 patients have been screened, 23 patients have been randomized (11 interventional group, 12 control group) in the coordinating center. Recruitment is expected to be completed in May 2019.

Abbreviations

AT: antithrombin; ECMO: Extracorporeal Membrane Oxygenation; AIFA: Agenzia Italiana del Farmaco; aPTT: activated partial thrombolplastin time; ACT: activated clotting time; PT: prothrombin time; ICI: Intensive Care Unit; eCRF: electronic case report from; IU: International Units; OR: odds ratio; EDTA: ethylenediaminetetraacetic acid; RPM: route per minute; TNF: tumor necrosis factor; IL:interleukin.

Ethics approval and consent to participate

Central ethical approval has been confirmed from the Milan Area B Ethics Committee (ref approval no. 191_2017bis) and we will not begin recruiting at other centers in the trial until local ethical approval has been obtained. Informed consent will be obtained from all the patients enrolled following local regulations.

Consent for publication

Not applicable.

Availability of data and material

Collected data will be entered in an electronic case report form (eCRF) available online at a dedicated website (https://ecmostudy.fbk.eu), with protected individual access for each participating center. The datasets used and/or analysed during the current study will be available from the corresponding author on reasonable request.

Competing interests

MP was awarded with GATRA Grifols Antithrombin Research Awards in 2016. He received payment and travel support for lectures from Shire® and Werfen ® Instrumentation Laboratory. GG received payment for lectures from Pfizer, Getinge, Draeger, Fisher&Paykel and support for travel/congress activities from Biotest and Getinge (all unrelated with the present manuscript). The other authors declare that they have no competing interests. Funding

The study is funded with the Grifols® Antithrombin Research Award (GATRA) 2016. Authors' contributions

MP and GG conceived the study and wrote the study protocol. AP and ES reviewed the study protocol for

important intellectual content. All authors reviewed the study protocol and approved the final version. MP, ES, AC, SD and EC collaborated in enrollment, treatment and data collection in the first patients. DC provided support for the statistical analysis. ES and MP drafted the present manuscript. All authors reviewed the present manuscript and approved the final version.

Acknowledgements

None.

1. Combes A, Brodie D, Bartlett R, Brochard L, Brower R, Conrad S, et al. Position paper for the organization of extracorporeal membrane oxygenation programs for acute respiratory failure in adult patients. Am J Respir Crit Care Med. 2014;190(5):488–96.

2. Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs. 1999;23(11):979–83.

3. Annich G, Adachi I. Anticoagulation for pediatric mechanical circulatory support. Pediatr Crit Care Med. 2013 Jun;14:S37-42.

4. Dalton HJ, Garcia-Filion P, Holubkov R, Moler FW, Shanley T, Heidemann S, et al. Association of bleeding and thrombosis with outcome in extracorporeal life support*. Pediatr Crit Care Med. 2015;16(2):167–74.

5. Oliver WC. Anticoagulation and Coagulation Management for ECMO. Seminars in cardiothoracic and vascular anesthesia. 2009 9;13(3):154–75.

6. ELSO. ELSO Anticoagulation Guideline. ELSO Anticoagulation Guideline. 2014.

7. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med. 2002;30(5 Suppl):S325-31.

8. Pratt CW, Church FC. Antithrombin: structure and function. Semin Hematol. 1991;28(1):3–9.

9. Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs. 2007;67(10):1429–40.

10. Protti A, LAcqua C, Panigada M. The delicate balance between pro-(risk of thrombosis) and anti-(risk of bleeding) coagulation during extracorporeal membrane oxygenation. Ann Transl Med. 2016;4(7):139–139.

11. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–47.

12. Panigada M, Iapichino G, L’Acqua C, Protti A, Cressoni M, Consonni D, et al. Prevalence Of “Flat-Line” Thromboelastography During Extracorporeal Membrane Oxygenation For Respiratory Failure In Adults. ASAIO J. 2015;

13. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effects of antithrombin III (AT III) and Trp49-modified AT III on plasma level of 6-keto-PGF1 alpha in rats. Thromb Res. 1995;80(3):201–8.

14. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis. 2002;13(8):657–70.

15. Wang J, Wang Y, Wang J, Gao J, Tong C, Manithody C, et al. Antithrombin is protective against myocardial ischemia and reperfusion injury. J Thromb Haemost. 2013;11(6):1020–8.

16. Isik S, Tuncyurek P, Zengin NI, Demirbag AE, Atalay F, Yilmaz S, et al. Antithrombin prevents apoptosis by regulating inflammation in the liver in a model of cold ischemia/warm reperfusion injury. Hepatogastroenterology. 2012;59(114):453–7.

17. dos Santos CC, Okutani D, Hu P, Han B, Crimi E, He X, et al. Differential gene profiling in acute lung injury identifies injury-specific gene expression. Crit Care Med. 2008 Mar;36:855–65.

18. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 2004 Sep;

19. Kemme MJB, Burggraaf J, Schoemaker RC, Kluft C, Cohen AF. Quantification of heparin-induced TFPI release: a maximum release at low heparin dose: Quantification of heparin induced TFPI release. British Journal of Clinical Pharmacology. 2002 Dec;54(6):627–34.

20. Wong TE, Delaney M, Gernsheimer T, Matthews DC, Brogan TV, Mazor R, et al. Antithrombin concentrates use in children on extracorporeal membrane oxygenation: a retrospective cohort study. Pediatr Crit Care Med. 2015 Mar;16:264–9.

21. Niebler RA, Christensen M, Berens R, Wellner H, Mikhailov T, Tweddell JS. Antithrombin replacement during extracorporeal membrane oxygenation. Artif Organs. 2011;35(11):1024–8.

22. Byrnes JW, Swearingen CJ, Prodhan P, Fiser R, Dyamenahalli U. Antithrombin III supplementation on extracorporeal membrane oxygenation: impact on heparin dose and circuit life. ASAIO J. 2014;60(1):57–62.

23. Nelson KM, Hansen LA, Steiner ME, Fischer GA, Dehnel J, Gupta S. Continuous Antithrombin III Administration in Pediatric Veno-Arterial Extracorporeal Membrane Oxygenation. The Journal of Pediatric Pharmacology and Therapeutics. 2017 Jul;22:266–71.

24. Ryerson LM, Bruce AK, Lequier L, Kuhle S, Massicotte MP, Bauman ME. Administration of antithrombin concentrate in infants and children on extracorporeal life support improves anticoagulation efficacy. ASAIO J. 2014;60(5):559–63.

25. Perry R, Stein J, Young G, Ramanathan R, Seri I, Klee L, et al. Antithrombin III administration in neonates with congenital diaphragmatic hernia during the first three days of extracorporeal membrane oxygenation. J Pediatr Surg. 2013 Sep;48(9):1837–42.

26. Martucci G, Panarello G, Occhipinti G, Ferrazza V, Tuzzolino F, Bellavia D, et al. Anticoagulation and Transfusions Management in Veno-Venous Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: Assessment of Factors Associated With Transfusion Requirements and Mortality. Journal of Intensive Care Medicine. 2017 Jan 1;885066617706339.

27. Iapichino GE, Protti A, Andreis DT, Panigada M, Artoni A, Novembrino C, et al. Antithrombin During Extracorporeal Membrane Oxygenation in Adults: National Survey and Retrospective Analysis. ASAIO J. 2018 May 8;

28. Aubron C, DePuydt J, Belon F, Bailey M, Schmidt M, Sheldrake J, et al. Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation. Ann Intensive Care. 2016 Dec;6:97.

29. Panigada M, Iapichino GE, Brioni M, Panarello G, Protti A, Grasselli G, et al. Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study. Ann Intensive Care. 2018 Jan 15;8:1–9.

supplement1.doc

Download PDF

Journal Publication

published 11 Jun, 2019

Read the published version in Trials →

Editorial decision: Accept
29 Apr, 2019
Submission checks completed at journal
24 Apr, 2019
Editor assigned by journal
24 Apr, 2019

You are reading this latest preprint version

Antithrombin Supplementation during Extracorporeal Membrane Oxygenation: Study Protocol for a Pilot Randomized Clinical Trial

Status:

Journal Publication

Version 2

Abstract

Figures

Background

Methods

Discussion

Trial Status

Declarations

References

Supplementary Files

Status:

Journal Publication

Version 2